{"meshTagsMajor":["Mutation"],"keywords":["EGFR mutations","Li-Fraumeni syndrome","Non-small cell lung cancer","TP53"],"meshTags":["Adult","Breast Neoplasms","DNA Mutational Analysis","Erlotinib Hydrochloride","Female","Humans","Li-Fraumeni Syndrome","Lung Neoplasms","Middle Aged","Mutation","Quinazolines","Receptor, Epidermal Growth Factor","Tomography, X-Ray Computed","Treatment Outcome","Tumor Suppressor Protein p53","Young Adult"],"meshMinor":["Adult","Breast Neoplasms","DNA Mutational Analysis","Erlotinib Hydrochloride","Female","Humans","Li-Fraumeni Syndrome","Lung Neoplasms","Middle Aged","Quinazolines","Receptor, Epidermal Growth Factor","Tomography, X-Ray Computed","Treatment Outcome","Tumor Suppressor Protein p53","Young Adult"],"genes":["EGFR","TP53 mutation","epidermal growth factor receptor","EGFR"],"publicationTypes":["Case Reports","Journal Article","Research Support, Non-U.S. Gov\u0027t"],"abstract":"This is a revised case report of a 52 year old Caucasian female with Li-Fraumeni syndrome with a rare TP53 mutation, who was treated for breast cancer and later developed epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer.","title":"EGFR-mutated lung cancer in Li-Fraumeni syndrome.","pubmedId":"25047674"}